All clinical oncology research at UTSW is coordinated by the Clinical Protocol and Data Management Shared Resource (Clinical Research Office;CRO). The CRO, along with the Protocol Review and Monitoring Committee (PRMC) and Data and Safety Monitoring Committee (DSMC), is part of the Protocol Review and Monitoring System (PRMS), which has direct oversight over all clinical oncology research activities at UTSW and the Cancer Center, and is responsible for oversight of all patient-related cancer research. Dr. Joan Schiller, Deputy Director of the Cancer Center, serves as Medical Director of the CRO. Ms. Lynn Baker, MBA, Assistant Director for Clinical Research, is the administrative director. The CRO serves as the clinical coordinating center for all activities related to clinical cancer research at UTSW. It provides infrastructure for oversight, management, and monitoring of oncology clinical trials, thus facilitating high quality clinical research throughout our campus. Centralization of these activities ensures standardization of all aspects of clinical research, ensuring patient safety and coordination of clinical research activities. The resource also provides a central location for cancer protocols, an updated list of currently active studies, status reports of protocols, and quality control and training for clinical research personnel and junior investigators. The CRO also provides administrative support for the PRMS and DSMC, including timely submission of all protocols, amendments, and regulatory documents;monitoring and auditing of SCC protocols to ensure compliance with all regulations;and accurate and timely submission of data to regulatory bodies. It assesses and assists with resource allocation, and standardizes operational policies and procedures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA142543-03
Application #
8380783
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$93,472
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Eskiocak, Banu; McMillan, Elizabeth A; Mendiratta, Saurabh et al. (2017) Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 7:832-851
Rutkowski, Joseph M; Pastor, Johanne; Sun, Kai et al. (2017) Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. Kidney Int 91:324-337
Singh, Jaspal; Rustagi, Vineeta; Zhang, Shanrong et al. (2017) On-bead combinatorial synthesis and imaging of europium(III)-based paraCEST agents aids in identification of chemical features that enhance CEST sensitivity. Magn Reson Chem 55:747-753
Singh, Dinesh K; Kollipara, Rahul K; Vemireddy, Vamsidara et al. (2017) Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma. Cell Rep 18:961-976
Gu, Yi-Feng; Cohn, Shannon; Christie, Alana et al. (2017) Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discov 7:900-917
Lee, Ming Y; Sumpter Jr, Rhea; Zou, Zhongju et al. (2017) Peroxisomal protein PEX13 functions in selective autophagy. EMBO Rep 18:48-60
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Howard, James J; Sturge, Carolyn R; Moustafa, Dina A et al. (2017) Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers. Antimicrob Agents Chemother 61:
Skinner, Celette Sugg; Ahn, Chul; Halm, Ethan A et al. (2017) Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk. Prev Med 102:20-23
Garcia, Sandra; Bisen, Ajit; Yan, Jingsheng et al. (2017) Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol 12:1489-1495

Showing the most recent 10 out of 441 publications